Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

<p>At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as...

Full description

Bibliographic Details
Main Authors:	V. A. Shuvaev, M. S. Fominykh, I. S. Martynkevich, V. Y. Udaleva, N. A. Potikhonova, M. N. Zenina, K. M. Abdulkadyrov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkogematologiâ
Subjects:	chronic myelogenous leukemia tyrosine kinase inhibitors imatinib dasatinib thrombocythopenia neutropenia romiplostim
Online Access:	http://oncohematology.abvpress.ru/index.php/ongm/article/view/12

id	doaj-1afb3b8b52094c91856fa9a22ed1a382
record_format	Article
spelling	doaj-1afb3b8b52094c91856fa9a22ed1a3822020-11-25T00:12:20ZrusABV-pressOnkogematologiâ1818-83462014-07-018471227Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patientsV. A. Shuvaev0M. S. Fominykh1I. S. Martynkevich2V. Y. Udaleva3N. A. Potikhonova4M. N. Zenina5K. M. Abdulkadyrov6Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological AgencyRussian Research Institute of Hematology and Transfusiology, Russian Federal Medico-Biological Agency<p>At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.</p>http://oncohematology.abvpress.ru/index.php/ongm/article/view/12chronic myelogenous leukemiatyrosine kinase inhibitorsimatinibdasatinibthrombocythopenianeutropeniaromiplostim
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov
spellingShingle	V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients Onkogematologiâ chronic myelogenous leukemia tyrosine kinase inhibitors imatinib dasatinib thrombocythopenia neutropenia romiplostim
author_facet	V. A. Shuvaev M. S. Fominykh I. S. Martynkevich V. Y. Udaleva N. A. Potikhonova M. N. Zenina K. M. Abdulkadyrov
author_sort	V. A. Shuvaev
title	Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
title_short	Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
title_full	Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
title_fullStr	Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
title_full_unstemmed	Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
title_sort	tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients
publisher	ABV-press
series	Onkogematologiâ
issn	1818-8346
publishDate	2014-07-01
description	<p>At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.</p>
topic	chronic myelogenous leukemia tyrosine kinase inhibitors imatinib dasatinib thrombocythopenia neutropenia romiplostim
url	http://oncohematology.abvpress.ru/index.php/ongm/article/view/12
work_keys_str_mv	AT vashuvaev tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT msfominykh tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT ismartynkevich tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT vyudaleva tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT napotikhonova tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT mnzenina tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients AT kmabdulkadyrov tyrosinekinaseinhibitorstherapyrelatedneutropeniaandthrombocythopeniacorrectionincmlpatients
_version_	1725399708775481344

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

Similar Items